Evolus Secures EU Approval For Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation; Broader Launch Planned For Late 2025
Portfolio Pulse from Benzinga Newsdesk
Evolus has received EU approval for its Estyme Injectable Hyaluronic Acid Gels under the new Medical Device Regulation, with a broader launch planned for late 2025.
October 31, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolus has obtained EU approval for its Estyme Injectable Hyaluronic Acid Gels, aligning with new Medical Device Regulation. A broader launch is planned for late 2025.
The EU approval under the new Medical Device Regulation is a significant milestone for Evolus, potentially expanding its market reach in Europe. The planned broader launch in 2025 suggests future revenue growth, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100